---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000614"
form_type: "8-K"
ticker: "ATAI"
cik: "0002081043"
company_name: "AtaiBeckley Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:16:09.694914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26

## Summary
- BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.
- Additional BPL-003 Phase 2a cohort evaluating two-dose induction in TRD starts Q1'26; initial data expected Q4'26.
- VLS-01 (DMT buccal film) Phase 2 Elumina trial topline data from 142 TRD patients expected H2'26.
- EMP-01 (oral R-MDMA) SAD Phase 2a topline data expected Q1'26; new patent provides exclusivity through 2043.
- Redomiciliation to Delaware completed Dec 2025; added to NASDAQ biotech index (NBI) Dec 2025; cash runway into 2029.

## SEC filing metadata
- accession: 0001140361-26-000614
- form_type: 8-K
- ticker: ATAI
- cik: 0002081043
- company_name: AtaiBeckley Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/0001140361-26-000614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/ef20062505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000614
- JSON: https://secwatch.observer/filing/0001140361-26-000614.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.